JP2008535493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535493A5 JP2008535493A5 JP2008505602A JP2008505602A JP2008535493A5 JP 2008535493 A5 JP2008535493 A5 JP 2008535493A5 JP 2008505602 A JP2008505602 A JP 2008505602A JP 2008505602 A JP2008505602 A JP 2008505602A JP 2008535493 A5 JP2008535493 A5 JP 2008535493A5
- Authority
- JP
- Japan
- Prior art keywords
- dendritic cells
- rna
- monocytes
- ratio
- mature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004443 Dendritic Cells Anatomy 0.000 claims 27
- 210000001616 Monocytes Anatomy 0.000 claims 15
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 9
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000038129 antigens Human genes 0.000 claims 4
- 108091007172 antigens Proteins 0.000 claims 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 102100011550 ACTB Human genes 0.000 claims 3
- 101700033661 ACTB Proteins 0.000 claims 3
- 101710032514 ACTI Proteins 0.000 claims 3
- 102100006400 CSF2 Human genes 0.000 claims 3
- 101710037135 GAPC2 Proteins 0.000 claims 3
- 101710037116 GAPC3 Proteins 0.000 claims 3
- 101710025049 GAPDG Proteins 0.000 claims 3
- 101710008404 GAPDH Proteins 0.000 claims 3
- 102100006425 GAPDH Human genes 0.000 claims 3
- 101710010461 Gapdh1 Proteins 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 101710025050 MK0970 Proteins 0.000 claims 3
- 101710025091 cbbGC Proteins 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 230000004069 differentiation Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 101710025070 gapdh-2 Proteins 0.000 claims 3
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100003729 CD40LG Human genes 0.000 claims 2
- 102100019451 CD80 Human genes 0.000 claims 2
- 101700080477 CD80 Proteins 0.000 claims 2
- 102100008186 CD83 Human genes 0.000 claims 2
- 101700013105 CD83 Proteins 0.000 claims 2
- -1 CD86 Proteins 0.000 claims 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 2
- 108020004999 Messenger RNA Proteins 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920002106 messenger RNA Polymers 0.000 claims 2
- 102100010730 ALOX15 Human genes 0.000 claims 1
- 101710022933 ALOX15 Proteins 0.000 claims 1
- 102000013135 CD52 Antigen Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 101700080416 CD69 Proteins 0.000 claims 1
- 102100005832 CD69 Human genes 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 101700068316 TLR1 Proteins 0.000 claims 1
- 102100002617 TLR1 Human genes 0.000 claims 1
- 101700064022 TLR2 Proteins 0.000 claims 1
- 102100012096 TLR2 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000001717 pathogenic Effects 0.000 claims 1
- 244000052769 pathogens Species 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000010257 thawing Methods 0.000 claims 1
- 229960005486 vaccines Drugs 0.000 claims 1
Claims (34)
- b.対象から単離されたときから約6〜96時間にわたり1℃〜34℃の温度においてインキュベートされた単球を用意し、そして
c.前記単球から樹状細胞への分化を誘導する
ことを含んでなる、単球から樹状細胞を作製するための方法。 - 前記単球がヒト単球である、請求項1に記載の方法。
- 前記インキュベート温度が6℃〜28℃である、請求項1に記載の方法。
- 前記インキュベート温度が8℃〜26℃である、請求項4に記載の方法。
- 前記インキュベート時間が8〜48時間である、請求項1に記載の方法。
- 前記インキュベート時間が10〜30時間である、請求項5に記載の方法。
- 前記インキュベート時間が26〜72時間である、請求項1に記載の方法。
- 前記インキュベート時間が48〜80時間である、請求項1に記載の方法。
- 単球から未成熟樹状細胞への分化を誘導する組成物の有効量を含んでなる培地と単球とを接触させることにより分化が誘導される、請求項1に記載の方法。
- 前記組成物がGM‐CSFおよびIL‐4、GM‐CSFおよびIL‐13、GM‐CSFおよびIL‐15、またはIFNαである、請求項9に記載の方法。
- 前記単球が、インキュベート時間の全部または一部にわたり、末梢血単核細胞(PBMC)と共存される、請求項1に記載の方法。
- 前記PBMCが白血球搬出法により対象から単離されたものである、請求項11に記載の方法。
- 前記単球が、インキュベート時間中またはその後に、PBMCから濃縮されたものである、請求項11に記載の方法。
- 未成熟樹状細胞を成熟樹状細胞へ成熟させる工程を更に含んでなる、請求項9に記載の方法。
- 抗原負荷樹状細胞を作製するために樹状細胞に1種以上の抗原を負荷させることを更に含んでなる、請求項1に記載の方法。
- 前記薬剤が少なくとも2%のDMSOを含んでなり、融解していつでも投与しうるものである、癌または病原体感染症の治療または予防用の凍結薬剤の製造に際する抗原負荷樹状細胞の使用。
- 前記薬剤が少なくとも10%のDMSOを含んでなるものである、請求項16に記載の使用。
- 請求項14に記載の方法により作製された樹状細胞を含んでなる組成物。
- 前記樹状細胞が抗原負荷されているものである、請求項18に記載の組成物。
- 前記樹状細胞がCD40LをコードするmRNAによりトランスフェクトされるものである、請求項19に記載の組成物。
- 前記成熟樹状細胞が、新鮮単球から作製された成熟樹状細胞と比較して、CD80、CD83、CD86、MHCクラスI分子、またはMHCクラスII分子のうち1種以上を高レベルで有するものである、請求項18に記載の組成物。
- 前記成熟樹状細胞が、新鮮単球から作製された成熟樹状細胞と比較して、CD80、CD83、CD86、MHCクラスI分子、またはMHCクラスII分子のうち1種以上を高レベルで有するものである、成熟単球由来樹状細胞を含んでなる組成物。
- 前記成熟樹状細胞がCD40LをコードするmRNAにより一時的にトランスフェクトされるものである、請求項22に記載の組成物。
- 細胞中ALOX15 RNA対β‐アクチンRNAまたはGAPDH RNAの定常状態比が1.0未満である、成熟単球由来樹状細胞。
- 前記比率が0.2〜0.7である、請求項24に記載の樹状細胞。
- 前記比率が0.4〜0.5である、請求項25に記載の樹状細胞。
- 細胞中CD52 RNA対β‐アクチンRNAまたはGAPDHの定常状態比が1.0より大きい、成熟単球由来樹状細胞。
- 前記比率が1.2〜5.0である、請求項27に記載の樹状細胞。
- 前記比率が1.5〜2.2である、請求項28に記載の樹状細胞。
- 前記比率が1.8〜1.9である、請求項29に記載の樹状細胞。
- 細胞中TLR1 RNA、TLR2 RNA、IL‐1β RNA、またはCD69 RNA対β‐アクチンRNAまたはGAPDH RNAの定常状態比が1.0未満である、成熟単球由来樹状細胞。
- 前記比率が0.2〜0.9である、請求項31に記載の樹状細胞。
- 前記比率が0.5〜0.8である、請求項32に記載の樹状細胞。
- 請求項18〜33のいずれか一項に記載の組成物を含んでなるワクチン。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66946805P | 2005-04-08 | 2005-04-08 | |
US60/669,468 | 2005-04-08 | ||
PCT/US2006/013159 WO2006127150A2 (en) | 2005-04-08 | 2006-04-07 | Dendritic cell compositions and methods |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008535493A JP2008535493A (ja) | 2008-09-04 |
JP2008535493A5 true JP2008535493A5 (ja) | 2009-05-28 |
JP5020935B2 JP5020935B2 (ja) | 2012-09-05 |
Family
ID=36992670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008505602A Active JP5020935B2 (ja) | 2005-04-08 | 2006-04-07 | 樹状細胞組成物および方法 |
Country Status (12)
Country | Link |
---|---|
US (6) | US8153425B2 (ja) |
EP (1) | EP1882031B1 (ja) |
JP (1) | JP5020935B2 (ja) |
KR (6) | KR20130061753A (ja) |
CN (1) | CN101155914B (ja) |
AU (1) | AU2006249640C1 (ja) |
CA (1) | CA2602434C (ja) |
ES (1) | ES2650569T3 (ja) |
IL (2) | IL185977A0 (ja) |
MX (1) | MX2007012221A (ja) |
NO (1) | NO345353B1 (ja) |
WO (1) | WO2006127150A2 (ja) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8513008B2 (en) * | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
EA015266B1 (ru) * | 2005-12-08 | 2011-06-30 | Дандрит Биотек А/С | Способ получения зрелых дендритных клеток для индуцирования иммунного ответа и применение полученных клеток |
JP5630781B2 (ja) | 2006-04-14 | 2014-11-26 | アドバンスド セル テクノロジー、インコーポレイテッド | 血管コロニー形成細胞 |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US8524495B2 (en) | 2007-05-16 | 2013-09-03 | Yale University | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
KR100935826B1 (ko) | 2007-11-27 | 2010-01-08 | 주식회사 바이넥스 | 부유밀도구배 원심분리를 이용하여 말초혈액단핵구로부터 단세포를 분리하는 방법 |
WO2009108341A1 (en) | 2008-02-28 | 2009-09-03 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
KR101689124B1 (ko) * | 2008-03-27 | 2016-12-23 | 아스테리아스 바이오세라퓨틱스, 인크. | 영장류 다능성 줄기 세포의 조혈계 세포로의 분화 |
CN110075113A (zh) | 2008-04-17 | 2019-08-02 | Pds生物科技公司 | 通过阳离子脂质的对映体刺激免疫应答 |
JP2012508241A (ja) * | 2008-11-04 | 2012-04-05 | イデラ ファーマシューティカルズ インコーポレイテッド | アンチセンスオリゴヌクレオチドによるToll様受容体2発現の調節 |
CA2774140A1 (en) | 2009-09-14 | 2011-03-17 | Baylor Research Institute | Vaccines directed to langerhans cells |
AU2010326027A1 (en) * | 2009-12-04 | 2012-06-21 | Stem Cell & Regenerative Medicine International, Inc. | Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts |
EP2547360A4 (en) * | 2010-03-15 | 2013-11-20 | Univ Pennsylvania | SYSTEM AND METHOD FOR THE PRODUCTION AND STORAGE OF ACTIVATED TIRES OF DENDRITIC CELLS |
ES2543795T3 (es) | 2010-03-31 | 2015-08-21 | Stabilitech Ltd. | Estabilización de partículas virales |
BR112012025047A2 (pt) | 2010-03-31 | 2016-06-21 | Stabilitech Ltd | formulações líquidas estabilizadas |
DK2552410T3 (en) | 2010-03-31 | 2019-02-18 | Stabilitech Biopharma Ltd | PROCEDURE FOR THE CONSERVATION OF ALUNADUVANCES AND VACCINES WITH ALUNADUVANCES |
US20130011438A1 (en) * | 2011-07-05 | 2013-01-10 | SOTIO a.s. | Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells |
GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
CN109536446B (zh) * | 2012-02-10 | 2022-08-02 | 医疗法人社团博心厚生会 | 单核细胞增殖剂、单核细胞增殖用培养基、及单核细胞的制造方法 |
EP2857498B1 (en) | 2012-05-31 | 2018-04-25 | JW Creagene Inc. | Composition for maturing dendritic cells, and method for preparing antigen-specific dendritic cells using same |
JP2015530413A (ja) | 2012-09-21 | 2015-10-15 | ベデュ−アッド,フランク | 改良されたワクチン組成物および使用方法 |
EP3626743A1 (en) * | 2013-02-01 | 2020-03-25 | Kira Biotech Pty Limited | Anti-cd83 antibodies and use thereof |
MX369521B (es) * | 2013-03-15 | 2019-11-11 | Genzyme Corp | Metodos de creacion de bancos de celulas de alta densidad. |
CA2940163C (en) * | 2014-02-21 | 2022-05-17 | Argos Therapeutics, Inc. | Tscm cells and methods for use |
CN103948917A (zh) * | 2014-04-02 | 2014-07-30 | 江苏和泽生物科技有限公司 | 树突状细胞疫苗的制备方法 |
GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
KR101518972B1 (ko) | 2014-08-01 | 2015-05-18 | 제이더블유크레아젠 주식회사 | 수지상세포의 제조방법, 이에 의해 제조된 수지상세포 및 그 용도 |
CN106999518A (zh) * | 2014-11-14 | 2017-08-01 | 日本赤十字社 | 脐带血以及末梢血的冻结保存方法以及冻结保存用溶液 |
EP3316897A4 (en) * | 2015-07-02 | 2019-03-13 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS |
US11612652B2 (en) * | 2015-11-13 | 2023-03-28 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
JP6779616B2 (ja) * | 2015-12-25 | 2020-11-04 | 富士ソフト株式会社 | Nkt細胞活性化医薬組成物、その製造方法、及び抗原提示細胞の保存方法 |
WO2017218533A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
EP3678701A4 (en) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF |
CA3081616A1 (en) | 2017-11-07 | 2019-05-16 | Coimmune, Inc. | Methods and uses for dendritic cell therapy |
US20200330576A1 (en) * | 2018-01-08 | 2020-10-22 | The Regents Of The University Of Michigan | Aldh1 antigen-pulsed dendritic cells |
WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
EA202190267A1 (ru) | 2018-07-15 | 2021-05-17 | Инокиан Байофарма, Инк. | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака |
KR102159766B1 (ko) * | 2018-11-12 | 2020-09-24 | 조선대학교산학협력단 | 홍조류추출물을 이용한 미성숙수지상세포 분화유도용 배지조성물 및 미성숙수지상세포 분화유도방법 |
JP2022525928A (ja) * | 2019-03-21 | 2022-05-20 | ガミダ セル リミテッド | 併用療法における移植に適したnk細胞画分の増殖及び増殖nk細胞画分の使用 |
CN114621921A (zh) * | 2020-12-11 | 2022-06-14 | 深圳先进技术研究院 | 一种提取神经突触体的方法 |
CN113980901B (zh) * | 2021-12-28 | 2022-06-17 | 上海惠盾因泰生物科技有限公司 | 一种制备高纯度的成熟人树突状细胞的方法及应用 |
WO2023245609A1 (en) * | 2022-06-24 | 2023-12-28 | Lihpao Life Science Corp. | Method for producing mature dendritic cells |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
JP2002514047A (ja) | 1996-07-10 | 2002-05-14 | イミュネックス・コーポレーション | 樹状細胞を活性化する方法 |
US20050084966A1 (en) * | 1999-04-20 | 2005-04-21 | Edelson Richard L. | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
EP1176986B1 (en) | 1999-04-20 | 2018-07-04 | Yale University | Differentiation of monocytes into functional dendritic cells |
US20050158856A1 (en) | 1999-04-20 | 2005-07-21 | Edelson Richard L. | Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials |
IT1312570B1 (it) * | 1999-05-28 | 2002-04-22 | Genera Spa | Metodo per il traferimento di antigeni a cellule dendritiche. |
DE10041515A1 (de) * | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
EP1270732A1 (en) | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
FR2833271B1 (fr) | 2001-12-10 | 2004-09-17 | Coletica | Production de cellules dendritiques in vitro a partir de monocytes cd14+, pour notamment la realisation de modeles cellulaires et/ou tissulaires en suspension, en monocouches et tridimentionnels; utilisation de ces modeles |
EP3173141B1 (en) | 2002-06-19 | 2019-09-04 | NorthWest Biotherapeutics, Inc. | Tangential flow filtration device and methods for leukocyte enrichment |
EP1389480A1 (en) * | 2002-08-14 | 2004-02-18 | Mondobiotech Interferon SA | Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation |
EP2301356A3 (en) * | 2002-12-04 | 2012-05-30 | Baylor Research Institute | Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors |
CN1264974C (zh) * | 2003-01-17 | 2006-07-19 | 江西医学院 | 白血病细胞诱导生成树突状细胞的培养基及其培养方法与应用 |
RU2364625C2 (ru) | 2003-02-27 | 2009-08-20 | Норсуэст Байотерапьютикс, Инк. | Генерирование дендритных клеток из моноцитарных предшественников дендритных клеток с помощью gm-csf в отсутствие дополнительных цитокинов |
JP5058804B2 (ja) | 2004-09-14 | 2012-10-24 | アルゴス セラピューティクス,インコーポレイティド | 病原体の株非依存的増幅およびそれに対するワクチン |
KR101243577B1 (ko) | 2004-10-07 | 2013-03-20 | 아고스 쎄라퓨틱스, 인코포레이티드 | 성숙 수지상 세포 조성물 및 그의 배양 방법 |
US8513008B2 (en) * | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
-
2006
- 2006-04-07 CN CN2006800113802A patent/CN101155914B/zh active Active
- 2006-04-07 US US11/918,076 patent/US8153425B2/en not_active Ceased
- 2006-04-07 KR KR1020137010879A patent/KR20130061753A/ko not_active Application Discontinuation
- 2006-04-07 US US14/450,092 patent/USRE46152E1/en not_active Expired - Fee Related
- 2006-04-07 KR KR1020207016974A patent/KR20200072566A/ko not_active Application Discontinuation
- 2006-04-07 KR KR1020077025609A patent/KR101368035B1/ko active IP Right Grant
- 2006-04-07 AU AU2006249640A patent/AU2006249640C1/en active Active
- 2006-04-07 KR KR20157005703A patent/KR20150032915A/ko not_active Application Discontinuation
- 2006-04-07 JP JP2008505602A patent/JP5020935B2/ja active Active
- 2006-04-07 KR KR1020177020072A patent/KR20170086700A/ko active Search and Examination
- 2006-04-07 MX MX2007012221A patent/MX2007012221A/es active IP Right Grant
- 2006-04-07 CA CA2602434A patent/CA2602434C/en active Active
- 2006-04-07 KR KR1020167009557A patent/KR20160045151A/ko active Search and Examination
- 2006-04-07 WO PCT/US2006/013159 patent/WO2006127150A2/en active Application Filing
- 2006-04-07 EP EP06749566.3A patent/EP1882031B1/en active Active
- 2006-04-07 ES ES06749566.3T patent/ES2650569T3/es active Active
-
2007
- 2007-09-17 IL IL185977A patent/IL185977A0/en unknown
- 2007-10-10 NO NO20075166A patent/NO345353B1/no unknown
-
2012
- 2012-01-17 US US13/351,510 patent/US8501470B2/en active Active
-
2013
- 2013-06-28 US US13/929,889 patent/US20130280805A1/en not_active Abandoned
-
2014
- 2014-04-03 IL IL231889A patent/IL231889A/en active IP Right Grant
- 2014-06-18 US US14/307,991 patent/US20150132844A1/en not_active Abandoned
-
2015
- 2015-10-09 US US14/879,336 patent/US20160102291A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008535493A5 (ja) | ||
Park et al. | MicroRNA-146a and microRNA-146b regulate human dendritic cell apoptosis and cytokine production by targeting TRAF6 and IRAK1 proteins | |
Maynard et al. | Diversity in the contribution of interleukin‐10 to T‐cell‐mediated immune regulation | |
Goddard et al. | Interleukin-10 secretion differentiates dendritic cells from human liver and skin | |
Zhang et al. | Mesenchymal stem cells alleviate bacteria‐induced liver injury in mice by inducing regulatory dendritic cells | |
Min et al. | TGF-β-associated miR-27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by TAB3, p38 MAPK, MAP2K4 and MAP2K7 | |
Wang et al. | Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T‐cell tolerance | |
Shin et al. | Human periodontal ligament stem cells suppress T‐cell proliferation via down‐regulation of non‐classical major histocompatibility complex‐like glycoprotein CD 1b on dendritic cells | |
Amado et al. | Cross‐regulation between cytokine and microRNA pathways in T cells | |
Kumar Kingsley et al. | Role of MicroRNAs in the development and function of innate immune cells | |
Zhang et al. | IFN-γ induced by IL-12 administration prevents diabetes by inhibiting pathogenic IL-17 production in NOD mice | |
Lin et al. | Chitosan as an adjuvant-like substrate for dendritic cell culture to enhance antitumor effects | |
JP2004536615A5 (ja) | ||
Chiang et al. | Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate | |
Jia et al. | The role of prostaglandin E2 receptor signaling of dendritic cells in rheumatoid arthritis | |
CN104278012A (zh) | 一种成人调节性t细胞体外扩增培养基及其使用方法 | |
Liu et al. | Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK) | |
Landi et al. | Dendritic cells matured by a prostaglandin E2-containing cocktail can produce high levels of IL-12p70 and are more mature and Th1-biased than dendritic cells treated with TNF-α or LPS | |
Croci et al. | Human dental pulp stem cells modulate cytokine production in vitro by peripheral blood mononuclear cells from coronavirus disease 2019 patients | |
Naoe et al. | Bacillus Calmette‐Guérin‐pulsed dendritic cells stimulate natural killer T cells and γδT cells | |
Nail et al. | Exosomal miRNA-mediated intercellular communications and immunomodulatory effects in tumor microenvironments | |
Thorne et al. | Tumor necrosis factor–α promotes survival and phenotypic maturation of poly (I: C)-treated dendritic cells but impairs their Th1 and Th17 polarizing capability | |
Holmstrøm et al. | Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy | |
Monasterio et al. | Immunostimulatory activity of low-molecular-weight hyaluronan on dendritic cells stimulated with Aggregatibacter actinomycetemcomitans or Porphyromonas gingivalis | |
Son et al. | Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells |